CN101443327A - 抑制香草素受体亚型1（vr1）受体的苯并二氢吡喃基脲化合物及其用途 - Google Patents

抑制香草素受体亚型1（vr1）受体的苯并二氢吡喃基脲化合物及其用途 Download PDF

Info

Publication number
CN101443327A
CN101443327A CNA2005800467732A CN200580046773A CN101443327A CN 101443327 A CN101443327 A CN 101443327A CN A2005800467732 A CNA2005800467732 A CN A2005800467732A CN 200580046773 A CN200580046773 A CN 200580046773A CN 101443327 A CN101443327 A CN 101443327A
Authority
CN
China
Prior art keywords
alkyl
dihydro
indazol
methyl
benzopyran
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800467732A
Other languages
English (en)
Chinese (zh)
Inventor
A·R·戈姆特塞安
E·K·贝伯特
R·G·小施米德特
C·-H·李
S·B·布朗
K·T·金克森
R·J·克尼希
F·J·达宁
S·拉特肖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CN101443327A publication Critical patent/CN101443327A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2005800467732A 2004-11-24 2005-11-22 抑制香草素受体亚型1（vr1）受体的苯并二氢吡喃基脲化合物及其用途 Pending CN101443327A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63063604P 2004-11-24 2004-11-24
US60/630,636 2004-11-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2011100508496A Division CN102161653A (zh) 2004-11-24 2005-11-22 抑制香草素受体亚型1(vr1)受体的苯并二氢吡喃基脲化合物及其用途

Publications (1)

Publication Number Publication Date
CN101443327A true CN101443327A (zh) 2009-05-27

Family

ID=36588346

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2005800467732A Pending CN101443327A (zh) 2004-11-24 2005-11-22 抑制香草素受体亚型1（vr1）受体的苯并二氢吡喃基脲化合物及其用途
CN2011100508496A Pending CN102161653A (zh) 2004-11-24 2005-11-22 抑制香草素受体亚型1(vr1)受体的苯并二氢吡喃基脲化合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2011100508496A Pending CN102161653A (zh) 2004-11-24 2005-11-22 抑制香草素受体亚型1(vr1)受体的苯并二氢吡喃基脲化合物及其用途

Country Status (13)

Country Link
US (2) US7812019B2 (https=)
EP (2) EP1844038A2 (https=)
JP (2) JP4932730B2 (https=)
KR (2) KR20120137420A (https=)
CN (2) CN101443327A (https=)
AU (1) AU2005316972B2 (https=)
BR (1) BRPI0518581A2 (https=)
CA (1) CA2588909A1 (https=)
IL (1) IL183321A0 (https=)
MX (1) MX2007006205A (https=)
NZ (1) NZ555318A (https=)
TW (1) TW200633712A (https=)
WO (1) WO2006065484A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103739547A (zh) * 2014-01-03 2014-04-23 沈阳药科大学 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
CN116783165A (zh) * 2020-09-30 2023-09-19 天主教鲁汶大学 作为用于治疗癌症的yap/taz-tead激活抑制剂的1,2,3,4-四氢喹啉衍生物

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086331A2 (en) * 2004-03-02 2005-09-15 Rosemount, Inc. Process device with improved power generation
US8538560B2 (en) 2004-04-29 2013-09-17 Rosemount Inc. Wireless power and communication unit for process field devices
US8145180B2 (en) * 2004-05-21 2012-03-27 Rosemount Inc. Power generation for process devices
KR20120137420A (ko) * 2004-11-24 2012-12-20 아보트 러보러터리즈 바닐로이드 수용체 아형 1(ｖｒ1) 수용체를 억제하는 크로마닐우레아 화합물 및 이의 용도
WO2006078697A1 (en) * 2005-01-18 2006-07-27 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
CN101203505A (zh) 2005-04-22 2008-06-18 惠氏公司 苯并二氢吡喃和苯并吡喃衍生物及其用途
TW200819441A (en) * 2005-10-28 2008-05-01 Abbott Lab Prodrugs of compounds that inhibit TRPV1 receptor
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
JP2009534399A (ja) * 2006-04-18 2009-09-24 アボット・ラボラトリーズ バニロイド受容体サブタイプ１型（ｖｒ１）の拮抗薬およびその使用
US7913566B2 (en) 2006-05-23 2011-03-29 Rosemount Inc. Industrial process device utilizing magnetic induction
WO2008059339A2 (en) * 2006-11-13 2008-05-22 Glenmark Pharmaceuticals S.A. Isoquinoline derivatives as vanilloid receptor modulators
WO2008079683A2 (en) * 2006-12-20 2008-07-03 Abbott Laboratories N- (5, 6, 7, 8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as trpv1 vanilloid receptor antagonists for the treatment of pain
WO2008110863A1 (en) * 2007-03-15 2008-09-18 Glenmark Pharmaceuticals S.A. Indazole derivatives and their use as vanilloid receptor ligands
WO2009078999A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
WO2009095726A1 (en) * 2008-01-29 2009-08-06 Glenmark Pharmaceuticals, S.A. Acrylamide derivatives as vanilloid receptor 1 modulators
JP5305704B2 (ja) * 2008-03-24 2013-10-02 富士フイルム株式会社 新規化合物、光重合性組成物、カラーフィルタ用光重合性組成物、カラーフィルタ、及びその製造方法、固体撮像素子、並びに、平版印刷版原版
US8250924B2 (en) 2008-04-22 2012-08-28 Rosemount Inc. Industrial process device utilizing piezoelectric transducer
US8929948B2 (en) 2008-06-17 2015-01-06 Rosemount Inc. Wireless communication adapter for field devices
EP2310918B1 (en) * 2008-06-17 2014-10-08 Rosemount, Inc. Rf adapter for field device with variable voltage drop
CA2726707C (en) 2008-06-17 2016-01-19 Rosemount Inc. Rf adapter for field device with low voltage intrinsic safety clamping
US8694060B2 (en) 2008-06-17 2014-04-08 Rosemount Inc. Form factor and electromagnetic interference protection for process device wireless adapters
WO2010023512A1 (en) * 2008-08-28 2010-03-04 Matrix Laboratories Ltd. Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them
US8609692B2 (en) * 2008-10-17 2013-12-17 Abbvie Inc. TRPV1 antagonists
CN102186836A (zh) * 2008-10-17 2011-09-14 雅培制药有限公司 Trpv1拮抗剂
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CN101654435B (zh) * 2009-06-09 2014-01-29 沈阳药科大学 N-苯甲基喹啉羧酸类化合物、组合物及其制备方法
US20100318007A1 (en) * 2009-06-10 2010-12-16 O'brien Donald J Electromechanical tactile stimulation devices and methods
US8626087B2 (en) 2009-06-16 2014-01-07 Rosemount Inc. Wire harness for field devices used in a hazardous locations
US9674976B2 (en) 2009-06-16 2017-06-06 Rosemount Inc. Wireless process communication adapter with improved encapsulation
CN102066372B (zh) 2009-08-24 2014-09-17 苏州爱斯鹏药物研发有限责任公司 含脲基的5，6元杂芳双环化合物作为激酶抑制剂
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
CA2794153C (en) 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
US10761524B2 (en) 2010-08-12 2020-09-01 Rosemount Inc. Wireless adapter with process diagnostics
TW201302681A (zh) 2011-03-25 2013-01-16 Abbott Lab Ｔｒｐｖ１拮抗劑
US9310794B2 (en) 2011-10-27 2016-04-12 Rosemount Inc. Power supply for industrial process field device
US8859584B2 (en) 2011-12-19 2014-10-14 Abbvie, Inc. TRPV1 antagonists
WO2013096226A1 (en) * 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
US9783527B2 (en) * 2014-09-16 2017-10-10 Abbvie Inc. Indazole ureas and method of use
CN109574972A (zh) * 2018-07-13 2019-04-05 郑州大学 一种3-烷基取代-4-色满酮类化合物及其制备方法
CN120398870A (zh) * 2024-01-31 2025-08-01 深圳晶蛋生物医药科技有限公司 一种苯并吗啉类化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386839B1 (en) * 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
NL8900565A (nl) 1989-03-08 1990-10-01 Philips Nv Methode voor de verwerking van een radio data signaal, alsmede ontvanger voor de uitvoering van deze methode.
US5374643A (en) 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
EP0922028A1 (en) 1996-08-26 1999-06-16 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
WO2001036403A1 (en) 1999-11-16 2001-05-25 Boehringer Ingelheim Pharmaceuticals, Inc. Urea derivatives as anti-inflammatory agents
WO2003097586A1 (en) * 2002-05-17 2003-11-27 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
US7514562B2 (en) 2003-03-07 2009-04-07 Glaxo Group Limited Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
KR20120137420A (ko) * 2004-11-24 2012-12-20 아보트 러보러터리즈 바닐로이드 수용체 아형 1(ｖｒ1) 수용체를 억제하는 크로마닐우레아 화합물 및 이의 용도
TW200819441A (en) 2005-10-28 2008-05-01 Abbott Lab Prodrugs of compounds that inhibit TRPV1 receptor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103739547A (zh) * 2014-01-03 2014-04-23 沈阳药科大学 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
CN116783165A (zh) * 2020-09-30 2023-09-19 天主教鲁汶大学 作为用于治疗癌症的yap/taz-tead激活抑制剂的1,2,3,4-四氢喹啉衍生物

Also Published As

Publication number Publication date
US8440691B2 (en) 2013-05-14
KR20070086607A (ko) 2007-08-27
BRPI0518581A2 (pt) 2008-11-25
US7812019B2 (en) 2010-10-12
IL183321A0 (en) 2008-04-13
AU2005316972A1 (en) 2006-06-22
JP2012111766A (ja) 2012-06-14
WO2006065484A3 (en) 2009-02-19
EP2527339A1 (en) 2012-11-28
TW200633712A (en) 2006-10-01
AU2005316972B2 (en) 2011-11-10
CA2588909A1 (en) 2006-06-22
EP1844038A2 (en) 2007-10-17
JP4932730B2 (ja) 2012-05-16
WO2006065484A2 (en) 2006-06-22
KR20120137420A (ko) 2012-12-20
KR101250824B1 (ko) 2013-04-05
CN102161653A (zh) 2011-08-24
US20110152250A1 (en) 2011-06-23
JP2008532925A (ja) 2008-08-21
MX2007006205A (es) 2009-02-13
US20060128689A1 (en) 2006-06-15
NZ555318A (en) 2011-01-28

Similar Documents

Publication Publication Date Title
CN101443327A (zh) 抑制香草素受体亚型1（vr1）受体的苯并二氢吡喃基脲化合物及其用途
TWI892960B (zh) 胺基酸化合物及使用方法
CN101759645B (zh) p38抑制剂及它们的使用方法
CN104822687B (zh) 抗纤维化吡啶酮类
JP6358639B2 (ja) ６員複素環誘導体およびそれらを含有する医薬組成物
CN106536491B (zh) 作为盐皮质激素受体调节剂的苯并噁嗪酮酰胺
WO2016112637A1 (zh) Btk抑制剂
JP2021535207A (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
WO2018119395A1 (en) Compouns, compositions and methods of use
CA2608184A1 (en) N,n-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors
KR20150106895A (ko) Ship1 조절제 및 그와 관련된 방법
WO2020117877A1 (en) Compounds, compositions and methods of use
MX2013002530A (es) Compuestos heterociclicos para tratar o prevenir trastornos causados por neurotransmision reducida de serotonina, norepinefrina o dopamina.
KR20260005244A (ko) 치환된 티오펜 융합 유도체, 이를 포함하는 조성물, 및 의약품으로서의 이들의 용도
CN119948023A (zh) 含哌啶多环类衍生物调节剂、其制备方法和应用
CN115260195B (zh) Egfr降解剂
UA58534C2 (uk) Похідні 2,3-(1н, 4н)-хіноксаліндіону, фармацевтична комозиція, спосіб лікування, проміжна сполука (варіанти), спосіб одержання сполуки (варіанти)
JP6692113B2 (ja) ６員複素環誘導体を含有する医薬組成物
WO2024158872A1 (en) 1,3-indole-propanamide inhibitors of sars-cov-2 plpro/nsp3 and derivatives thereof
HK40016947B (en) Anti-fibrotic pyridinones
HK1260632A1 (en) Anti-fibrotic pyridinones
HK40008995A (en) Substituted carbonucleoside derivatives useful as anticancer agents
HK1239679A1 (en) Piperidine derivative and preparation method and pharmaceutical use thereof
HK1147480A (en) Heterocyclic compounds with affinity to muscarinic receptors
HK1198476B (en) Imidazoline derivatives, preparation methods thereof, and their applications in medicine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20090527